MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) reported Q1 2026 results and key advances in its allo-iNKT cell therapy platform.
The company initiated a randomized Phase 2 agenT-797 trial in severe acute lung injury/critical illness with preliminary data expected in 2H 2026, expanded non-dilutive collaborations, repaid $5.2M of debt, and ended the quarter with $9.5M in cash and a $2.7M net loss.
Positive
- Randomized Phase 2 agenT-797 trial in acute lung injury and critical illness initiated
- Preliminary Phase 2 agenT-797 trial data expected in the second half of 2026
- PD-1 refractory gastroesophageal cancer study showed 77% disease control rate
- Gastroesophageal cancer patients with immune induction had 6.9 vs 3.5 months median PFS
- C-Further collaboration provides up to ~$1.1M in non-dilutive funding with potential double-digit revenue participation
- Additional externally supported programs backed by NIH STTR funding and philanthropic support
- Completed repayment of ~$5.2M Agenus convertible note, reducing debt
- Q1 2026 net loss slightly lower at $2.7M versus $2.8M in Q1 2025
- Raised ~$3.0M through at-the-market sales agreement in Q1 2026
Negative
- Cash and cash equivalents declined to $9.5M from $13.4M at year-end 2025
- Q1 2026 net loss of ~$2.7M and net loss per share of $0.57
- Cash used in operations increased to $1.7M from $1.3M year over year
News Market Reaction – INKT
In the May 15 session, INKT gained 2.00%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Q3 2025 earnings | Positive | -3.6% | Reported Q3 2025 results with durable iNKT responses and extended cash runway. |
| Aug 14 | Q2 2025 earnings | Positive | -12.5% | Q2 2025 results with durable remission, DoD grants, and post-quarter equity raise. |
| Jul 31 | Earnings call notice | Neutral | -8.3% | Scheduled Q2 2025 results and corporate update call with access details. |
| May 15 | Q1 2025 earnings | Positive | -4.3% | Q1 2025 results with testicular cancer remission and reduced cash burn. |
| May 05 | Earnings call notice | Neutral | -0.1% | Announced timing of Q1 2025 results and conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related communications have consistently been followed by negative next-day moves, even when updates highlighted clinical advances and funding progress.
Over the past year, MiNK’s earnings and related updates have emphasized iNKT platform progress and non-dilutive funding. Q1 and Q2 2025 results highlighted complete remissions, grant support, and improved cash burn, while later Q3 2025 results stressed durable responses and runway through 2026. Despite these clinically and strategically positive messages, the stock moved lower after each of the last 5 earnings-linked announcements, underscoring a pattern of weak market response to this news type.
Key Terms
randomized phase 2 medical
interleukin-15 superagonist medical
invariant natural killer t medical
allogeneic medical
acute respiratory distress syndrome medical
investigator-sponsored medical
at-the-market financial
convertible note financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026
- AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease
- Non-dilutive collaborations expand MiNK’s platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programs
- Company continues disciplined execution with reduced operating burn and focused advancement of high-priority programs
- New clinical data to be presented at the ATS conference on May 20, 2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported financial results for the first quarter ending March 31, 2026, and provided a corporate update.
“MiNK entered 2026 focused on converting a growing body of clinical and translational evidence into prospective validation,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “During the first quarter and subsequent period, we advanced agenT-797 into a randomized Phase 2 study in acute lung injury and critical illness, presented data that further support the context-dependent biology of iNKT cells, and continued to expand the platform through selective, non-dilutive collaborations. This is the next phase of MiNK’s strategy: disciplined clinical execution, rigorous translational validation, and capital-efficient expansion of a broadly deployable cell therapy platform.”
Dr. Buell continued, “What continues to distinguish agenT-797 is both its biology and its practicality. As an off-the-shelf iNKT cell therapy administered without lymphodepletion or HLA matching, agenT-797 is designed for settings where immune dysfunction drives poor outcomes and where speed, tolerability and deployability matter. We believe this is particularly relevant in severe acute lung injury and critical illness, where patients often face a cascade of respiratory failure, secondary infection and organ dysfunction with limited therapeutic options.”
Recent Business and Development Highlights
agenT-797 Advanced into Randomized Phase 2 Clinical Evaluation in Acute Lung Injury and Critical Illness
MiNK initiated a randomized Phase 2 clinical trial evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with severe acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure due to severe pneumonia, who meet Global ARDS criteria and are admitted to the ICU. The study is being designed with a seamless Phase 2/3 operational framework intended to support efficient transition into later-stage development if findings from the randomized Phase 2 portion are prospectively confirmed.
The trial has received authorization from the Ukraine Ministry of Health, is supported by an active U.S. IND, and remains subject to FDA clearance for planned U.S. site activation. Preliminary data are expected in the second half of 2026.
Acute lung injury and ARDS remain among the most serious unresolved conditions in critical care. ARDS affects an estimated 3 million patients globally and approximately 200,000 patients annually in the United States, accounting for nearly
Recent Data at AACR and ASGCT Strengthen the Biologic Rationale for Context-Dependent iNKT Activity
Recent clinical and translational presentations at the American Association for Clinical Research (AACR) Annual Meeting and the American Society of Gene and Cell Therapy Meeting (ASGCT) reinforced the potential of MiNK’s iNKT platform to generate disease-relevant immune activity across distinct clinical settings.
In PD-1 refractory gastroesophageal cancer, investigator-sponsored Phase 2 data showed disease control and longer-term survival in a subset of heavily pretreated patients, supported by evidence of immune activation and tumor microenvironment remodeling. The study achieved a
At ASGCT, translational analyses showed that the same off-the-shelf agenT-797 product generated distinct immune outputs in solid tumor and ARDS patients. In solid tumor patients, agenT-797 was associated with a TH1 pro-inflammatory signature consistent with anti-tumor immune activation. In ARDS patients, the same product was associated with a TH2 anti-inflammatory signature consistent with immune restoration and lung injury recovery.
Together, these findings support MiNK’s broader development strategy: advancing agenT-797 in settings where immune dysfunction contributes to poor outcomes, while using translational data to define patient populations, biologic mechanisms and future development pathways.
Non-Dilutive Collaborations Support Capital-Efficient Platform Expansion
MiNK continued to advance its strategy of expanding the iNKT platform through selective collaborations that provide external support and potential downstream economics while preserving focus on lead clinical programs.
In the first quarter, MiNK announced a collaboration with C-Further, an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration provides up to approximately
The C-Further program applies MiNK’s off-the-shelf iNKT platform to a validated tumor antigen strategy in pediatric oncology and reflects the company’s broader approach to platform expansion through externally supported, capital-efficient development.
MiNK is also advancing additional externally supported programs, including its graft-versus-host disease program supported by NIH STTR funding and the Mary Gooze philanthropic award. These collaborations and funding sources are intended to support pipeline progress while reducing the capital burden typically associated with multi-program cell therapy development.
Upcoming ATS Presentation Extends Platform Discussion into Persistent Pulmonary Infection and Immune Dysfunction
MiNK will present clinical data featuring agenT-797 at the American Thoracic Society (ATS) International Conference 2026. The presentation, titled “Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection,” will be presented by Terese Hammond, M.D., and in collaboration with ImmunityBio (NASDAQ: IBRX) on May 20, 2026.
In accordance with ATS guidelines, no data or results have been disclosed prior to the conference. The presentation is expected to expand the platform discussion beyond oncology and acute inflammatory lung injury into persistent infection, immune dysfunction and pathogen control, areas where MiNK believes immune restoration may have broader therapeutic relevance.
Financial Results
MiNK ended the first quarter of 2026 with approximately
Net loss for the first quarter of 2026 was approximately
| Summary Consolidated Financial Information | |||||
| Condensed Consolidated Balance Sheet Data | |||||
| (in thousands) | |||||
| (unaudited) | |||||
| March 31, 2026 | December 31, 2025 | ||||
| Cash and cash equivalents | $ | 9,526 | $ | 13,360 | |
| Other Financial Information | |||||
| (in thousands) | |||||
| (unaudited) | |||||
| Three months ended March 31, | |||||
| 2026 | 2025 | ||||
| Net loss | $ | 2,742 | $ | 2,767 | |
| Net loss per share | 0.57 | 0.70 | |||
| Cash used in operations | $ | 1,733 | $ | 1,341 | |
First Quarter 2026 Financial Results Conference Call and Webcast
MiNK will host a conference call and webcast today at 8:30 a.m. ET to discuss its financial results and corporate update.
Conference Call and Webcast Information
| United States – New York USA & Canada – Toll-Free Conference ID – | (646) 307-1963 (800) 715-9871 4876136 |
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link: https://edge.media-server.com/mmc/p/n4ak2xfn
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
_________________________
References
i Cleveland Clinic. Acute Respiratory Distress Syndrome (ARDS).
ii Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788–800.
